Progesterone receptor (PR, or PgR) assay is used together with ER to identify patients eligible for post-operative hormonal therapies. Tumors positive for both receptors respond best to anti-estrogen or aromatase inhibitor therapies. Approximately 50-70% of invasive breast tumors are PR-positive.
Scoring of the slides can be done quantitatively using the histoscore method (% of positive cells x staining intensity; 0-4), or qualitatively using three classes (-, +., and ++).
PR negative
PR positive
PR positive
All material on this website is protected by
copyright. By accessing or downloading contents
from this website, you expressly agree and consent to
our terms and conditions.
publications
